StreetInsider.com News Articles

Alumis shares Phase 3 data on envudeucitinib for plaque psoriasis

Fri, 09 Oct 2026 04:00:17 -0400

Alumis Inc. (Nasdaq: ALMS) presented new Phase 3 clinical data for its investigational drug envudeucitinib at the 26th Annual Fall Clinical Dermatology Conference, showing improvements in scalp clearance, itch relief, and quality of life in patients with moderate-to-severe plaque psoriasis.

The data came from the ONWARD clinical program, which includes trials ONWARD1, ONWARD2, and the long-term extension ONWARD3, with a combined enrollment of more than 1,700 patients. Key findings included:

More than 80% of patients in ONWARD3 maintained clear or nearly clear scalp skin at 48 weeks. In ONWARD1 and ONWARD2, approximately one-third of patients achieved clinically meaningful itch reduction by Week

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Fri, 09 Oct 2026 04:00:00 -0400

– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis

– Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48

– On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Fri, 09 Oct 2026 04:00:00 -0400

– Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48

– On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026

H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Mon, 05 Oct 2026 06:43:42 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $15.00 price target on Alumis Inc (NASDAQ: ALMS).

The analyst commented: "Full LATITUDE Atlas results showed zaso produced Week 16 PASI 100 of 36.5% vs. 13.9%, PASI 90 of 62.5% vs. 34.0%, and sPGA 0 of 43.2% vs. 18.5% with Sotyktu. While Takeda had already disclosed statistical superiority, the magnitude of separation is important because it shows that next-generation TYK2 inhibition can deliver a clear clinical step-up from the first approved agent rather than merely adding another oral option with similar efficacy. We view that as favorable for Alumis: Takeda’s

Alumis (ALMS) Reiterated at Overweight by Cantor Fitzgerald

Wed, 16 Sep 2026 07:55:15 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Alumis Inc (NASDAQ: ALMS).

The analyst commented, "Our derms, working in academic centers, are biologics people and not the key prescriber base for next-gen orals. They expect oral IL-23 Icotyde (JNJ, NC) to find a market, but think orals in psoriasis face a higher bar than in AD given existing every-12-week biologic options. TB testing is viewed as a barrier to uptake for Sotyktu, so our derms will be looking to see if this will be a requirement for the next-gen TYK2i's from ALMS (OW, ES) and TAK (NC)."

For an analyst

Guggenheim Downgrades Alumis Inc (ALMS) to Neutral

Wed, 02 Sep 2026 16:35:57 -0400

Guggenheim analyst Yatin Suneja downgraded Alumis Inc (NASDAQ: ALMS) from Buy to Neutral.

The analyst comments "ALMS's Phase IIb SLE study (n=408) evaluating Envudeucitinib (oral TYK2i) missed both primary and secondary endpoints in the overall population. Post-hoc subgroup analysis in IFNG-high patients showed encouraging clinical responses, which supports moving forward with Phase III development, per mgmt. While we think the most likely path forward is to conduct two Phase III studies (which would likely take ~2-3 years), we expect to hear future updates regarding Phase III design, sizing, dosing, and the enrollment criteria related to desired IFNGS status. Until then, we

Guggenheim Downgrades Alumis Inc (ALMS) to Neutral

Wed, 02 Sep 2026 16:35:57 -0400

Guggenheim analyst Yatin Suneja downgraded Alumis Inc (NASDAQ: ALMS) from Buy to Neutral.

Alumis Inc (ALMS) PT Lowered to $37 at Oppenheimer

Wed, 02 Sep 2026 07:55:56 -0400

Oppenheimer analyst Jeff Jones lowered the price target on Alumis Inc (NASDAQ: ALMS) to $37.00 (from $55.00) while maintaining a Outperform rating.

Alumis Inc (ALMS) PT Lowered to $29 at Morgan Stanley

Wed, 02 Sep 2026 06:26:14 -0400

Morgan Stanley analyst Terence Flynn lowered the price target on Alumis Inc (NASDAQ: ALMS) to $29.00 (from $39.00) while maintaining a Overweight rating.

The analyst comments "ALMS reported that a Ph2 SLE/lupus trial of key pipeline drug Envudeucitinib (Envu; oral TYK2i) failed to meet the primary and secondary endpoints and shares traded down -57% (vs. S&P 500 -0.7%) - see our first take HERE. The company hosted a conference call and provided more details on the prespecified subgroup of patients with high interferon gene signature (IFNGS), placebo behavior, and imputation methodology and shared that they plan to discuss the Ph3 path

Alumis Inc (ALMS) PT Lowered to $29 at Morgan Stanley

Wed, 02 Sep 2026 06:26:14 -0400

Morgan Stanley analyst Terence Flynn lowered the price target on Alumis Inc (NASDAQ: ALMS) to $29.00 (from $39.00) while maintaining a Overweight rating.

Alumis Inc (ALMS) PT Lowered to $27 at Baird

Wed, 02 Sep 2026 06:17:19 -0400

Baird analyst Brian Skorney lowered the price target on Alumis Inc (NASDAQ: ALMS) to $27.00 (from $35.00) while maintaining a Outperform rating.

Alumis Inc (ALMS) PT Lowered to $25 at Wells Fargo

Wed, 02 Sep 2026 05:13:49 -0400

Wells Fargo analyst Derek Archila lowered the price target on Alumis Inc (NASDAQ: ALMS) to $25.00 (from $51.00) while maintaining a Overweight rating.

The analyst comments "How we are thinking about valuation: This is the tricky part, envu's PsO oppty deserves value but how much? Assuming a co-co, we get to $13/shr as mgmt reiterated to us they do not plan to launch themselves. Mgmt had highlighted previously waiting for the SLE data prior to making strategic decisions, which is needed to add to their cash runway. We assign a 35% POS (from 75%) for SLE worth ~$6/sh based on today's

Alumis Inc (ALMS) PT Lowered to $25 at Wells Fargo

Wed, 02 Sep 2026 05:13:49 -0400

Wells Fargo analyst Derek Archila lowered the price target on Alumis Inc (NASDAQ: ALMS) to $25.00 (from $51.00) while maintaining a Overweight rating.

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

Alumis Inc. (Nasdaq: ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population, according to a company statement.

The trial enrolled 408 patients who received one of three envudeucitinib doses or placebo over 48 weeks. The primary endpoint measured overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48.